|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K2317/21 | (2013.01) | ||
| A61K 39/00 | (2006.01) | ||
| C07K2317/73 | (2013.01) | ||
| C07K2317/522 | (2013.01) | ||
| C07K2317/524 | (2013.01) | ||
| C07K2317/92 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K 16/2878 | (2013.01) | ||
| C07K2317/72 | (2013.01) | ||
| C07K2317/75 | (2013.01) |
| (11) | Number of the document | 3423489 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16736717.6 |
| Date of filing the European patent application | 2016-06-28 | |
| (97) | Date of publication of the European application | 2019-01-09 |
| (45) | Date of publication and mention of the grant of the patent | 2024-08-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/039785 |
| Date | 2016-06-28 |
| (87) | Number | WO 2017/151176 |
| Date | 2017-09-08 |
| (30) | Number | Date | Country code |
| 201662304012 P | 2016-03-04 | US |
| (72) |
RAVETCH, Jeffrey, V. , US
DAHAN, Rony , US
|
| (73) |
The Rockefeller University ,
1230 York Avenue, New York, NY 10065,
US
|
| (54) | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY |
| ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY |